A Study to Assess the Safety of TPM502 in Adults With Celiac Disease

This is a multi center, double-blind, randomized, placebo-controlled Phase 2a study to evaluate the safety, tolerability, and PD effects of two infusions of TPM502 in adult patients diagnosed with CeD.

The patient´s participation in the study comprises 3 phases: screening period, treatment period and follow-up period.

Patients fulfilling the eligibility criteria will be randomized to receive two infusions of TMP502 (or placebo) at the same dose level. Patients will undergo a second GC one week after the second infusion of TPM502.

The study includes 4 cohorts of patients, each cohort will receive escalating doses of TPM502 (or placebo). Upon completion of the 3rd cohort, a lower dose can be investigated, if deemed relevant.

Inclusion criteria

• Availability of a documented biopsy-confirmed diagnosis of CeD OR documented tissue transglutaminase >10x ULN and documented positive IgA anti-endomysial antibody (EMA) at time of CeD diagnosis (as per local guidelines)
• Serum anti-tissue transglutaminase 2 immunoglobin A antibodies within normal range (i.e., <15 U/mL) at screening
• Serum IL-2 levels (AUC1-6h) above a pre-defined threshold following the GC at screening
• Patients must have been on GFD for ≥ 6 months
• Patients must have well-controlled CeD, defined as mild or with no ongoing signs or symptoms felt to be related to active CeD, as per investigator's assessment
• HLA-DQ2.5 positive

Exclusion criteria

• Known or suspected refractory CeD (refractory CeD type I or II)
• Known intolerable symptoms following previous GCs, as per investigator's assessment
• HLA DQ8 positive
• Any active gastrointestinal disease such as gastroesophageal reflux disease, esophagitis or peptic ulcer, microscopic colitis, or irritable bowel syndrome, which in the opinion of the investigator might interfere with the assessment of the symptoms related to CeD
• Known history of or active Crohn's disease, ulcerative colitis, or ulcerative jejunitis
• Known wheat allergy
• Known hypersensitivity to i.v. iron preparations or any other excipients present in the reconstituted TPM502 or placebo